GT Biopharma, Inc. - FORM 10-Q - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE

Attached files

file	filename
EX-10.2 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH MICHAEL HANDELMAN, DATED APRIL 23 - GT Biopharma, Inc.	gtbp_ex102.htm
10-Q - QUARTERLY REPORT - GT Biopharma, Inc.	gtbp_10-q.htm
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc.	gtbp_ex322.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.	gtbp_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.	gtbp_ex311.htm
EX-10.3 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH DR. GREGORY BERK, DATED APRIL 23, - GT Biopharma, Inc.	gtbp_ex103.htm
EX-10.1 - AMENDED AND RESTATED EMPLOYMENT AGREEMENT WITH ANTHONY CATALDO, DATED APRIL 23, - GT Biopharma, Inc.	gtbp_ex101.htm

Exhibit 32.1

CERTIFICATION TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, I, Anthony Cataldo, Chief Executive Officer of GT Biopharma, Inc. (the “Company”), hereby certify that, to the best of my knowledge:

(i) the Quarterly Report on Form 10-Q of the Company for the fiscal quarter ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.



Date: May 17, 2021	By:	/s/ Anthony Cataldo
		Name: Anthony Cataldo
		Title: Chief Executive Officer, Chairman and Director

Attached files

Stock widget

Investing forum

GT Biopharma, Inc. Reports